ArticleUrology case reports2023
Primary adenocarcinoma of the renal pelvis in spina bifida patient with history of simple cystectomy.
Article in Urology case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Brachytherapy for choroidal metastasis secondary to primary urethral adenocarcinoma of Müllerian origin: A case report.American journal of ophthalmology case reports · 2025Article
- A Rare Presentation in a Common Renal Anomaly: Metastatic Adenocarcinoma in a Horseshoe Kidney.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary renal adenocarcinomas comprise of less than 1% of renal and ureteral epithelial tumors. We present a case of a 67-year-old male with a history of simple cystectomy who underwent left nephroureterectomy for primary enteric-type renal adenocarcinoma with cystitis glandularis features. Pathological examination confirmed grade 2 pT1N0MX primary enteric-type renal adenocarcinoma. The patient underwent left open radical nephroureterectomy, with an uneventful postoperative course. Surgical excision is the mainstay treatment, while chemotherapy and radiation are potential adjuncts. Prognosis remains poor, with a 50% overall survival rate within two years of surgery. Further research is needed to enhance treatment recommendations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.